6-Month Safety And Efficacy Study Of TTP488 In Patients With Type 2 Diabetes And Persistent Albuminuria

NCT00287183

Last updated date
Study Location
Pfizer Investigational Site
Red Deer, Alberta, T4N 6V7, Canada
Contact
1-800-718-1021
ClinicalTrials.gov_Inqui[email protected]

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Diabetic Nephropathy
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
31 + years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Male or female outpatients 31 years of age or older.

- Females must no longer be of child-bearing potential, must have a negative serum pregnancy test, and cannot be breast-feeding.

- Non-vasectomized male must be willing to abstain from sexual intercourse or willing to use a condom in addition to having their female partner use another form of contraception.

- Diagnosis of probable Type 2 diabetes after the age of 30 and for at least 6 months prior to the screening visit and: not requiring insulin within first year of diagnosis; no history of diabetic ketoacidosis (DKA); body mass index (BMI) of 40 or less at the screening visit

- Presence of persistent albuminuria with a UACR of 6.7 - 203 mg/mmol Must be taking the highest tolerated dose of an angiotensin converting enzyme (ACE) inhibitor or an angiotensin II receptor blocker (ARB) and have been maintained on that dose for at least 3 months prior to the Baseline visit

- Blood pressure(BP) must be stable and well controlled by the judgement of the investigator (goal of the control of BP is 130/80 or less). If required, the use of anti-hypertensives in addition to an ACE inhibitor or an ARB is acceptable.

- Patients with a calculated creatinine clearance of greater than or equal to 30 mL/min and without the presence of clinically significant hematuria or red or white cell casts can be included in the study.

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- Diagnosis of Type 1 diabetes


- Hemoglobin A1c (HbA1c) >10%


- Females cannot be breast-feeding


- Known renal artery stenosis


- Calculated creatinine clearance <30 mL/min or the presence of clinically significant
hematuria of red or white cell casts


- Chronic use of NSAIDs or more than 1 g/day of aspirin


- QTc >450 msec for females or >430 msec for males (a measure of the time between the
start of the Q wave and the end of the T wave in the heart's electrical cycle)


- Known family history of prolonged QT syndrome


- History of symptomatic congestive heart failure within the last 2 years


- History of syncope in the lst 2 years or recurrent hypokalemia, including that caused
by diuretics


- Myocardial infarction or signs or symptoms of unstable coronary artery disease with
the last year


- Pulmonary disease or evidence of clinically significant pulmonary symptoms.


- Active neoplastic disease. (Excised cutaneous basal cell carcinomas are not excluded).
Patients with stable prostate cancer may be included at the discretion of the Medical
Monitor.


- Any clinically significant hematologic or coagulation disorder


- Any clinically significant hepatic disease


- Use of excluded medications: drugs known to significantly increase QTc and/or have
increased risk of torsades de point, immunosuppressive agents, cancer chemotherapeutic
agents, oral corticosteroids other than maintenance doses equivalent to 7.5 mg
prednisone per day, and radiotherapy


- Use of an investigational drug within 30 days or within 5 half-lives of the
investigational agent, whichever is longer, or use of an investigational medical
device within 2 weeks before or after the study


- Any other disease or condition that, in the opinion of the investigator, makes the
patient unsuitable to participate in this study

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Diabetic Nephropathy6-Month Safety And Efficacy Study Of TTP488 In Patients With Type 2 Diabetes And Persistent Albuminuria NCT00287183
  1. Red Deer, Alberta
  2. Penticton, British Columbia
  3. Vancouver, British Columbia
  4. Burlington, Ontario
  5. Courtice, Ontario
  6. Fort Erie, Ontario
  7. Hamilton, Ontario
  8. Kitchener, Ontario
  9. Kitchener, Ontario
  10. Millon, Ontario
  11. North Bay, Ontario
  12. Oakville, Ontario
  13. Saint Catherines, Ontario
  14. Scarborough, Ontario
  15. Smith Falls, Ontario
  16. Thornhill, Ontario
  17. Toronto, Ontario
  18. Toronto, Ontario
  19. Saskatoon, Saskatchewan
ALL GENDERS
31 Years+
years
MULTIPLE SITES
Diabetic NephropathyA Phase 2 Multi-Center Study To Evaluate The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Antagonist In Adults With Type 2 Diabetes And Overt Nephropathy NCT01712061
  1. Little Rock, Arkansas
  2. Azusa, California
  3. Chula Vista, California
  4. Covina, California
  5. Huntington Beach, California
  6. Los Angeles, California
  7. Los Gatos, California
  8. North Hollywood, California
  9. Palm Springs, California
  10. Salinas, California
  11. San Dimas, California
  12. Aurora, Colorado
  13. Clearwater, Florida
  14. Doral, Florida
  15. Hialeah, Florida
  16. Miami Springs, Florida
  17. Miami, Florida
  18. Miami, Florida
  19. Miami, Florida
  20. Miami, Florida
  21. New Port Richey, Florida
  22. New Port Richey, Florida
  23. New Port Richey, Florida
  24. Pembroke Pines, Florida
  25. Champaign, Illinois
  26. Paducah, Kentucky
  27. Metairie, Louisiana
  28. New Orleans, Louisiana
  29. New Orleans, Louisiana
  30. Bethesda, Maryland
  31. Springfield, Massachusetts
  32. Flint, Michigan
  33. Flint, Michigan
  34. Troy, Michigan
  35. Kansas City, Missouri
  36. Kansas City, Missouri
  37. Omaha, Nebraska
  38. Albuquerque, New Mexico
  39. Mineola, New York
  40. Mineola, New York
  41. Northport, New York
  42. Asheville, North Carolina
  43. Greenville, North Carolina
  44. Morehead City, North Carolina
  45. Statesville, North Carolina
  46. Winston-Salem, North Carolina
  47. Providence, Rhode Island
  48. Providence, Rhode Island
  49. Orangeburg, South Carolina
  50. Memphis, Tennessee
  51. Nashville, Tennessee
  52. Greenville, Texas
  53. Houston, Texas
  54. Houston, Texas
  55. Houston, Texas
  56. Richmond, Texas
  57. San Antonio, Texas
  58. San Antonio, Texas
  59. San Antonio, Texas
  60. Sugar Land, Texas
  61. Saint George, Utah
  62. Burke, Virginia
  63. Burke, Virginia
  64. Manassas, Virginia
  65. Milwaukee, Wisconsin
  66. Junin, Buenos Aires
  67. Mar del Plata, Buenos Aires
  68. Quilmes, Buenos Aires
  69. Corrientes,
  70. Santa Fe,
  71. Tucumán,
  72. Liverpool, New South Wales
  73. New Lambton, New South Wales
  74. Westmead, New South Wales
  75. Nambour, Queensland
  76. Box Hill, Victoria
  77. Clayton, Victoria
  78. Parkville, Victoria
  79. Vancouver, British Columbia
  80. Vancouver, British Columbia
  81. Courtice, Ontario
  82. Scarborough, Ontario
  83. Toronto, Ontario
  84. Toronto, Ontario
  85. Laval, Quebec
  86. Montreal, Quebec
  87. Montreal, Quebec
  88. St-Romuald, Quebec
  89. Herzberg, Brandenburg
  90. Aschaffenburg,
  91. Berlin,
  92. Dresden,
  93. Duesseldorf,
  94. Essen,
  95. Falkensee,
  96. Hannover,
  97. Hoyerswerda,
  98. Neuwied,
  99. Schwabenheim,
  100. Shatin, New Territories, Hong Kong SAR
  101. Shatin, New Territories, Hong Kong SAR
  102. Hong Kong,
  103. Bari, BA
  104. Lido Camaiore. (Lucca), Lucca
  105. Lido di Camaiore (LUCCA), Lucca
  106. Lido di Camaiore (LUCCA), Lucca
  107. Modena, MO
  108. Foggia,
  109. Lecco,
  110. Milano,
  111. Pavia,
  112. Seoul,
  113. Seoul,
  114. Seoul,
  115. Kubong Kerian, Kelantan
  116. Taiping, Perak
  117. Batu Caves, Selangor
  118. Lima,
  119. Lima,
  120. Lima,
  121. Lima,
  122. Piura,
  123. Krakow, Malopolskie
  124. Golub-Dobrzyn,
  125. Krakow,
  126. Krakow,
  127. Lodz,
  128. Lodz,
  129. Warszawa,
  130. Zamosc,
  131. Ponce,
  132. Rio Piedras,
  133. Oradea, jud. Bihor
  134. Bucuresti,
  135. Ploiesti,
  136. Timisoara,
  137. Hospitalet de Llobregat, Barcelona
  138. Majadahonda, Madrid
  139. Barcelona,
  140. Barcelona,
  141. Girona,
  142. Valencia,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE 6-Month Safety And Efficacy Study Of TTP488 In Patients With Type 2 Diabetes And Persistent Albuminuria
Official Title  ICMJE Double-Blind, Randomized, Placebo-Controlled, Phase IIa, Multicenter Study In Patients With Type 2 Diabetes And Persistent Albuminuria To Evaluate The Safety And Efficacy Of A Six Month Regimen Of Orally-Administered TTP488
Brief Summary Current research indicates that TTP488 may be a viable agent for the treatment of diabetic nephropathy. The purpose of this study is to determine the safety and efficacy of a six-month regimen of daily orally-administered TTP488 to patients with diabetic nephropathy.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Condition  ICMJE Diabetic Nephropathy
Intervention  ICMJE
  • Drug: PF-04494700 (TTP488)
    60 mg/day for 6 days followed by 20 mg/day for 175 days vs placebo, oral medication
  • Other: Placebo
    Placebo
Study Arms  ICMJE
  • Active Comparator: PF-04494700 (TTP488)
    Intervention: Drug: PF-04494700 (TTP488)
  • Placebo Comparator: Placebo
    Intervention: Other: Placebo
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: February 2, 2006)
110
Original Enrollment  ICMJE Same as current
Actual Study Completion Date  ICMJE August 2009
Actual Primary Completion Date August 2009   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Male or female outpatients 31 years of age or older.
  • Females must no longer be of child-bearing potential, must have a negative serum pregnancy test, and cannot be breast-feeding.
  • Non-vasectomized male must be willing to abstain from sexual intercourse or willing to use a condom in addition to having their female partner use another form of contraception.
  • Diagnosis of probable Type 2 diabetes after the age of 30 and for at least 6 months prior to the screening visit and: not requiring insulin within first year of diagnosis; no history of diabetic ketoacidosis (DKA); body mass index (BMI) of 40 or less at the screening visit
  • Presence of persistent albuminuria with a UACR of 6.7 - 203 mg/mmol Must be taking the highest tolerated dose of an angiotensin converting enzyme (ACE) inhibitor or an angiotensin II receptor blocker (ARB) and have been maintained on that dose for at least 3 months prior to the Baseline visit
  • Blood pressure(BP) must be stable and well controlled by the judgement of the investigator (goal of the control of BP is 130/80 or less). If required, the use of anti-hypertensives in addition to an ACE inhibitor or an ARB is acceptable.
  • Patients with a calculated creatinine clearance of greater than or equal to 30 mL/min and without the presence of clinically significant hematuria or red or white cell casts can be included in the study.

Exclusion Criteria:

  • Diagnosis of Type 1 diabetes
  • Hemoglobin A1c (HbA1c) >10%
  • Females cannot be breast-feeding
  • Known renal artery stenosis
  • Calculated creatinine clearance <30 mL/min or the presence of clinically significant hematuria of red or white cell casts
  • Chronic use of NSAIDs or more than 1 g/day of aspirin
  • QTc >450 msec for females or >430 msec for males (a measure of the time between the start of the Q wave and the end of the T wave in the heart's electrical cycle)
  • Known family history of prolonged QT syndrome
  • History of symptomatic congestive heart failure within the last 2 years
  • History of syncope in the lst 2 years or recurrent hypokalemia, including that caused by diuretics
  • Myocardial infarction or signs or symptoms of unstable coronary artery disease with the last year
  • Pulmonary disease or evidence of clinically significant pulmonary symptoms.
  • Active neoplastic disease. (Excised cutaneous basal cell carcinomas are not excluded). Patients with stable prostate cancer may be included at the discretion of the Medical Monitor.
  • Any clinically significant hematologic or coagulation disorder
  • Any clinically significant hepatic disease
  • Use of excluded medications: drugs known to significantly increase QTc and/or have increased risk of torsades de point, immunosuppressive agents, cancer chemotherapeutic agents, oral corticosteroids other than maintenance doses equivalent to 7.5 mg prednisone per day, and radiotherapy
  • Use of an investigational drug within 30 days or within 5 half-lives of the investigational agent, whichever is longer, or use of an investigational medical device within 2 weeks before or after the study
  • Any other disease or condition that, in the opinion of the investigator, makes the patient unsuitable to participate in this study
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 31 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Canada
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT00287183
Other Study ID Numbers  ICMJE B0341001
TTP488-202
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Director, Clinical Trials Disclosure Group, Pfizer, Inc.
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date September 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP